Alpha Tau's Alpha DaRT Shows 67% Complete Response in Recurrent Glioblastoma Trial
Event summary
- Alpha Tau's Alpha DaRT achieved 100% local disease control and 67% complete response rate in first three recurrent glioblastoma patients.
- One grade 3 serious adverse event (seizure with temporary paralysis) observed, later resolved.
- Trial conducted at The Ohio State University Comprehensive Cancer Center, with treatment dates in December 2025, February 2026, and March 2026.
- Conference call with principal investigator scheduled for May 11, 2026, at 8:30am ET.
The big picture
Alpha Tau's interim results position Alpha DaRT as a potential breakthrough in treating recurrent glioblastoma, a cancer with a median survival of under 12 months post-recurrence. The trial's early success could reshape treatment paradigms for one of oncology's most resistant diseases, though scaling from small patient cohorts to broader approval remains a critical hurdle. The company's ability to navigate regulatory pathways will determine the speed of potential commercialization.
What we're watching
- Regulatory Pathway
- Whether the FDA will confirm safety report and allow trial continuation.
- Clinical Efficacy
- The pace at which Alpha DaRT demonstrates durable responses in additional patients.
- Market Expansion
- How Alpha Tau will leverage these results to pursue further indications in brain cancer.
Related topics